Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 2): Clinical and Therapeutic Considerations
- PMID: 28401511
- PMCID: PMC5515667
- DOI: 10.1007/s12265-017-9736-2
Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 2): Clinical and Therapeutic Considerations
Abstract
Multiple phase III trials over the last few decades have failed to demonstrate a clear benefit of various pharmacologic interventions in heart failure with a preserved left ventricular (LV) ejection fraction (HFpEF). Therefore, a better understanding of its pathophysiology is important. An accompanying review describes key technical and physiologic aspects regarding the deep phenotyping of arterial hemodynamics in HFpEF. This review deals with the potential of this approach to enhance our clinical, translational, and therapeutic approach to HFpEF. Specifically, the role of arterial hemodynamics is discussed in relation to (1) the pathophysiology of left ventricular diastolic dysfunction, remodeling, and fibrosis, (2) impaired oxygen delivery to peripheral skeletal muscle, which affects peripheral oxygen extraction, (3) the frequent presence of comorbidities, such as renal failure and dementia in this population, and (4) the potential to enhance precision medicine approaches. A therapeutic approach to target arterial hemodynamic abnormalities that are prevalent in this population (particularly, with inorganic nitrate/nitrite) is also discussed.
Keywords: Afterload; Arterial hemodynamics; Comorbidities; Dementia; Exercise intolerance; Heart failure with preserved ejection fraction; Pulsatile load; Renal disease; Wave reflections.
Figures
Similar articles
-
Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 1): Physiologic and Technical Considerations.J Cardiovasc Transl Res. 2017 Jun;10(3):245-259. doi: 10.1007/s12265-017-9735-3. Epub 2017 Feb 16. J Cardiovasc Transl Res. 2017. PMID: 28210939 Free PMC article. Review.
-
The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction.Curr Heart Fail Rep. 2016 Feb;13(1):47-59. doi: 10.1007/s11897-016-0277-9. Curr Heart Fail Rep. 2016. PMID: 26792295 Free PMC article. Review.
-
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Circulation. 2016 Jul 5;134(1):73-90. doi: 10.1161/CIRCULATIONAHA.116.021884. Circulation. 2016. PMID: 27358439 Free PMC article. Review.
-
Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction.J Am Coll Cardiol. 2015 Oct 13;66(15):1672-82. doi: 10.1016/j.jacc.2015.07.067. J Am Coll Cardiol. 2015. PMID: 26449137 Clinical Trial.
-
Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction.J Am Heart Assoc. 2014 Dec 2;3(6):e001293. doi: 10.1161/JAHA.114.001293. J Am Heart Assoc. 2014. PMID: 25468660 Free PMC article.
Cited by
-
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review.J Am Coll Cardiol. 2021 Sep 14;78(11):1166-1187. doi: 10.1016/j.jacc.2021.07.014. J Am Coll Cardiol. 2021. PMID: 34503685 Free PMC article. Review.
-
Exercise-Induced Hypertension Is Associated With Gestational Hypertension Occurrence in Patients With Repaired Aortic Coarctation.JACC Adv. 2025 Jul;4(7):101863. doi: 10.1016/j.jacadv.2025.101863. Epub 2025 May 30. JACC Adv. 2025. PMID: 40449091 Free PMC article.
-
Impact of Diabetes Mellitus on Ventricular Structure, Arterial Stiffness, and Pulsatile Hemodynamics in Heart Failure With Preserved Ejection Fraction.J Am Heart Assoc. 2019 Feb 19;8(4):e011457. doi: 10.1161/JAHA.118.011457. J Am Heart Assoc. 2019. PMID: 30764699 Free PMC article. Clinical Trial.
-
Carotid wave analysis in young adults with a history of adolescent anorexia nervosa: a case control study.J Eat Disord. 2024 Feb 2;12(1):21. doi: 10.1186/s40337-023-00963-0. J Eat Disord. 2024. PMID: 38308371 Free PMC article.
-
Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.J Cardiovasc Transl Res. 2017 Jun;10(3):233-244. doi: 10.1007/s12265-017-9756-y. Epub 2017 Jun 5. J Cardiovasc Transl Res. 2017. PMID: 28585183 Free PMC article. Review.
References
-
- Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010;121:586–613. - PubMed
-
- Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, Heffernan KS, Lakatta EG, McEniery CM, Mitchell GF, Najjar SS, Nichols WW, Urbina EM, Weber T American Heart Association Council on H. Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. Hypertension. 2015;66:698–722. - PMC - PubMed
-
- Hoekstra T, Lesman-Leegte I, van Veldhuisen DJ, Sanderman R, Jaarsma T. Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. European Journal of Heart Failure. 2011;13:1013–1018. - PubMed
-
- Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. European Journal of Heart Failure. 2007;9:83–91. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
